The National Agency for Food and Drug Administration and Control, NAFDAC, is at variance with World Health Organisation, WHO, on the use of hydroxychloroquine for COVID-19 treatment.
WHO had announced its temporary suspension of all clinical trials of hydroxychloroquine for the treatment of COVID-19 patients citing a study, which claimed the likelihood of users dying of the virus is high.
Reacting, NAFDAC DG, Mojisola Adeyeye, on a television programme monitored on Tuesday said Nigeria will not toe the path of the UN agency.
Instead, the country’s use of hydroxychloroquine in clinical trial will continue.
“There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body,” the NAFDAC boss said.
